Skip to main content
. 2019 Jan;8(Suppl 1):S23–S47. doi: 10.21037/tcr.2018.10.06

Figure 3.

Figure 3

Schematic representation of the LUX-Lung program for the development of afatinib in NSCLC. NSCLC, non-small cell lung cancer.